INTRODUCTION
• Heart failure is the most common reason for hospitalisation among patients older than 65 years in Sweden [1] .
• Considering a prevalence of 2%, approximately 200,000 HF patients are affected with HF in Sweden [2] with an estimated annual direct costs of 2-2.6 billion SEK.
• Adherence to standard of care treatment with ACE inhibitors (ACEi) and beta blockers (BB) is high (>80%), but nonetheless readmission rate within 30 days after first hospitalization remains high (19.5%) and the prognosis of hospitalized patients is poor [3] .
• Sacubitril/valsartan (Entresto®) is an inhibitor of the angiotensin II receptor and neprilysin (ARNi) that improved outcomes in patients with reduced ejection fraction (HFrEF) 
METHODS

RESULTS
• In the base case, sacubitril/valsartan was associated with an ICER of 224,885 SEK (24,040 EUR**); Table 3 .
• Sacubitril/valsartan was associated with a longer life expectancy of around 10 months and a QALY gain of 0.48 compared to enalapril.
• While average annual therapy costs were higher with sacubitril/valsartan compared with an ACEi (16,307 vs 1,077 SEK or 1,743 vs 0,115 EUR**), non-therapy costs were lower (36,750 vs 40,076 SEK or 3,929 vs 4,284 EUR**).
CONCLUSIONS AND DISCUSSION
• Our analysis suggests that sacubitril/valsartan is cost-effective vs ACE inhibitors, the current standard of care, at conventional willingness-to-pay threshold in Sweden (<500,000 SEK), in a population of individuals with HFrEF and in New York Heart Association (NYHA) functional classes II-IV.
• Results showed to be robust throughout all sensitivity analyses. However, our analysis had one important limitation, which was that treatment effect had to be extrapolated beyond the clinical trial and the relative effect of sacubitril/valsartan on mortality was assumed to be maintained for the modelling period. This limitation was assessed in the scenario testing.
• The conclusions of this cost-effectiveness analyses is consistent with those of an independent analysis from the perspective of third-party health care payers in the US [10] , a US analysis performed by Gaziano et al [11] and the approval for use in the UK by the National Institute for Health and Care Excellence (NICE). 
OBJECTIVE
To evaluate the cost-effectiveness of sacubitril/valsartan (Entresto®), a novel angiotensin-receptor neprilysin inhibitor (ARNi), compared to enalapril in heart failure patients with reduced ejection fraction (HFrEF) from a Swedish health care perspective.
Table 1. Summary of cost assumptions and data
Treatment costs Costs (SEK) Assumptions and sources
Daily drug costs sacubitril/valsartan 42 [5] Titration cost for sacubitril/valsartan 5,339
Assumption: two GP visits, one NT-proBNP test and one outpatient specialist visit. Unit costs from [6] and [7] Daily drug costs enalapril 0.53 [5] Titration cost for enalapril (ACE-i) NA
Patients assumed to be already treated with ACE-I
Resource use
Unit costs for hospitalisation 54,532
Based on hospitalizations observed in PARADIGM-HF, costed using relevant DRG-codes for Sweden [6] and [8] Unit costs for GP visits 1, 199 Background management equally applied to both model arms. Cost estimate from [2] , inflated to 2015
Unit costs for adverse events 2,924-4,178
Costs dependent on observed AE in PARADIGM-HF (hypotension, cough, angioedema, elevated serum potassium and elevated serum creatinine)
Indirect unit costs for hospitalisation 515
Costs estimates for re-weighted SwedeHF population [9] Figure 2. Scatter plot and CEAC of probabilistic sensitivity analyses
• A regression based cost-effectiveness analysis of sacubitril/valsartan compared to ACEi was developed based on PARADIGM-HF data. (Figure 1 ).
• Regression analyses were used to predict events and outcomes as functions of treatment arm, baseline characteristics and time from randomization.
• Cardiovascular mortality was modelled using parametric survival curves (Gompertz distribution) derived from PARADIGM-HF data with non-CV mortality captured using Swedish life tables • All-cause hospitalization rates were estimated using a negative binomial regression model • Utilities were calculated based on a mixed model linking EQ-5D estimates to hospitalizations, adverse events, time from randomisation and treatment allocation.
• Adverse event rates were derived from PARADIGM-HF results, and assumed to be constant.
• Patient characteristics from the PARADIGM-HF population were re-weighted based on data from the Swedish Heart Failure Registry (SwedeHF) ( Table 2) [9].
• Swedish unit costs for treatment, monitoring, hospitalization and adverse events are summarised inTable 1.
• The model was run from a societal perspective and adopted a life-long investment horizon. Costs and outcomes were discounted at 3.0%, and the year for costs was 2015.
• The primary outcome was the incremental cost-effectiveness ratio (ICER), expressed as the cost per qualityadjusted life-year (QALY).
• Univariate sensitivity analysis was performed using 95% confidence interval for point estimates and a ± 25% range for costs. Additional scenario testing of modelling assumptions were performed to test the robustness of the model results.
• Joint parameter uncertainty was explored through probabilistic sensitivity analysis, where all parameters are assigned distributions (SD) and varied jointly; 1,000 Monte Carlo simulations. • Univariate sensitivity analysis suggested that these results were most sensitive to the coefficients in the regression of CV mortality; a variation of these between their 95% bounds yielded ICERs between 160,000 and 350,000 SEK (17,000 and 37,000 EUR**). The results of the scenario testing are shown in Table 4 .
• Based on the results of the probabilistic sensitivity analyses (scatter blot and cost-effectiveness acceptability curve (CEAC) in Figure 2 ) the probabilities of sacubitril/valsartan being cost-effective at the lifetime time horizon at thresholds of 300,000 SEK and 500,000 SEK (32,000 and 53,000 EUR**) were 95.2% and 99.9%, respectively.
• Weighted PARADGIM-HF based on SwedeHF (Table 2) Incremental cost Probability cost-effectiveness QALY gained Willingness to pay (SEK) 
